<DOC>
	<DOCNO>NCT02732678</DOCNO>
	<brief_summary>Adrenergic process stimulate epinephrine norepinephrine drive development tumor growth metastasis . Beta-adrenergic receptor ( BAR ) antagonists show efficacy melanoma , breast cancer prostate cancer . The non-specific BAR inhibitor propranolol use gold standard treatment pediatric patient benign infantile hemangioma express high level beta adrenergic receptor potentially explain sensitively propranolol . BAR show express across diverse panel vascular tumor , high expression malignant vascular tumor include angiosarcoma . Several report indicate positive result beta-blockade patient moderately threaten vascular tumor . It remain determined malignant vascular tumor angiosarcoma susceptible propranolol . Besides , due lack adequate therapy angiosarcoma ( doxorubicin paclitaxel finally cyclophosphamide third line ) poor prognosis rare aggressive tumor , strong need development treatment tumor type . Recently use panel angiosarcoma cell line . demonstrate beta-adrenergic inhibition block cell proliferation induces apoptosis dose dependent manner . Moreover , use vivo tumor model demonstrate propanolol show remarkable efficacy reduce growth angiosarcoma tumor . Based proofs mechanism vitro vivo due well establish safety propranolol human , investigator propose determine among wide range propranolol dose ( 80 mg/d ; 120 mg/d 160 mg/d ) optimal one base bivariate efficacy-toxicity outcome patient angiosarcoma treat cyclophosphamide . Because two drug different pharmacological mechanism , aim determine optimal dose propranolol best systemic cardiovascular tolerability best potential antiangiogenic effect addition cyclophosphamide .</brief_summary>
	<brief_title>Dose-Finding Propranolol Combination With Metronomic Fixed Oral Cyclophosphamide Based Bivariate Efficacy-tolerability Outcome Patients With Locally Advanced Metastatic Angiosarcoma : A Collaborative Innovative Phase I-II Sequential Trial French Sarcoma Group ( GSF/GETO )</brief_title>
	<detailed_description />
	<mesh_term>Hemangiosarcoma</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Adolescent &gt; 15 year body surface &gt; 1,6 m2 Histologically proven angiosarcoma , review independent pathologist , metastasis locally advanced stage amenable radiotherapy curativeintent surgery multidisciplinary decision ; Prior systemic treatment paclitaxel doxorubicin At least one lesion measurable accord RECIST , version 1.1 ; No brain meningeal metastasis ; No two prior line chemotherapy ( whatever indication ) ; A World Health Organization performance status score ≤2 ; Neutrophils count &gt; 1000 /mm3 , platelet count ≥100,000/mm3 , hemoglobin level ≥ 8 g/Dl , liver transaminase ≤1.5 XULN , total bilirubin ≤1.5X ULN , serum creatinine≤1.5XULN , amylase lipase≤1.5XULN Pregnant breastfeeding woman . Subject contraindication propranolol ( ie cardiogenic shock ; sinus bradycardia great firstdegree block ; Chronic Obstructive Pulmonary Disease bronchial asthma ; patient know hypersensitivity Propranolol ; assess cardiovascular pulmonary history examination include blood pressure , ECG ; untreated Pheochromocytoma , Congestive heart failure control treatment , Prinzmetal 's angina ) Subject Severe Raynaud Phenomena Raynaud Disease Subject Prior systemic treatment Cyclophosphamide 1st 2nd line</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>